CoagulationDisorders near Pompton Plains, NJ

Biography: Dr. Hua-Jay "Jeff" Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. His research on ctDNA in patients with relapsed lymphoma receiving chimeric antigen receptor T-cell therapy is funded by a Conquer Cancer Young Investigator Award grant. He is a member of Southwestern Oncology Group Lymphoma Working Group and Committee. He was selected to participate in the Academy of Next Wave of Investigators for non-Hodgkin's lymphoma and the American Society of Hematology Clinical Research Training Institute, competitive programs aimed at supporting academic and career development for promising clinical researchers. Dr. Cherng's goal is to design clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.

Biography: Dr. Deborah Doroshow, MD is a Hematology Specialist who practices in New York, NY. She is 42 years old. Dr. Deborah Doroshow, MD is affiliated with Mount Sinai Morningside and Mount Sinai Hospital.

Biography: Alexandra Gomez Arteaga, M.D., is Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital. She specializes in the care of patients with hematological malignancies and other disorders who need a blood or bone marrow stem cell transplant or cellular therapies.Dr. Gomez received her M.D. (Valedictorian) from Los Andes University in Bogota, Colombia, in 2011. She completed her Internal Medicine residency at the University of Miami/Jackson Memorial Hospital and her Hematology/Oncology fellowship at Weill Cornell Medicine/New York-Presbyterian Hospital, where she also served as Chief Fellow. Subsequently, she completed an advanced fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. Upon completion of her training, Dr. Gomez was recruited back to Weill Cornell Medicine/New York-Presbyterian Hospital to join the faculty of the Bone Marrow Transplant Program.Dr. Gomez's main research focus is relapse prevention strategies and management of disease relapse after a stem cell transplant. She has published in leading internationally circulated peer-reviewed journals, among them Cancer, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, the American Journal of Hematology, Leukemia & Lymphoma. She is a member of the American Society for Transplantation and Cellular Therapy (ASTCT), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the Society for Immunotherapy of Cancer (SITC).

Care Philosophy: I am a medical oncologist specializing in the treatment of patients with genitourinary malignancies (including prostate, bladder, testes, and kidney cancers). My clinical and translational research focuses on development of new treatment strategies for patients. In particular, I am studying the genetics of prostate cancer, and I am involved in developing personalized treatment approaches for patients based on their cancer's specific molecular alterations. My clinical practice and research rely on close collaborations with clinicians, scientists, and physician scientists from multiple disciplines including pathology, urology, radiology, radiation oncology, computational biology, pharmacology, and medical oncology. Most recently, we have expanded these clinical and research efforts across cancer types as part of our new Institute for Precision Medicine